Core Viewpoint - AbbVie's drug, Risankizumab injection, has been approved by the National Medical Products Administration for the treatment of moderate to severe active ulcerative colitis (UC) in adults who have inadequate response, loss of response, or intolerance to traditional therapies or biological agents, marking the second indication approval after Crohn's disease [1]. Group 1 - Risankizumab is the first IL-23 specific inhibitor approved for ulcerative colitis globally, providing a new treatment option for UC patients [1]. - Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to significant gastrointestinal symptoms and complications, with increasing incidence rates in China, particularly among young adults aged 20-49 [1]. - Approximately one-fifth of UC patients are unable to work or study due to their condition, and long-term disease can lead to psychological issues such as sleep disorders, fatigue, and anxiety [1]. Group 2 - The approval of Risankizumab is significant as it targets the IL-23 pathway, a key mechanism in the pathogenesis of ulcerative colitis, aiming to improve symptoms such as abdominal urgency, pain, and sleep disturbances [2]. - The goal of treatment emphasizes long-term stability of the disease without reliance on steroids, which is crucial for enhancing the quality of life for patients [2].

Core Points - The article discusses the inclusion of 19 new drugs in the commercial health insurance innovation drug directory, highlighting their significance in the pharmaceutical market [10] - It emphasizes the advancements in CAR-T therapies and their impact on treating various cancers, particularly multiple myeloma and acute lymphoblastic leukemia [11][14][17] - The article also mentions the introduction of innovative drugs targeting Alzheimer's disease, showcasing their potential to change treatment paradigms [25][28] Group 1: New Drug Listings - A total of 19 new drugs have been added to the commercial health insurance innovation drug directory, including notable entries like Bristol-Myers Squibb's ipilimumab injection and Green Leaf Pharmaceutical's albituzumab injection [10] - The list includes various companies such as Pfizer, Novartis, and Jiangsu Hengrui Medicine, indicating a diverse range of pharmaceutical players involved [2][3][4] Group 2: CAR-T Therapies - The article highlights the global first approval of fully human CAR-T therapies, specifically targeting BCMA for treating relapsed or refractory multiple myeloma, with a five-year overall survival rate of 76.9% [12] - It mentions the efficacy of the CAR-T drug targeting GD2 for high-risk neuroblastoma, which has shown a real-world effectiveness rate exceeding 90% [14] - The introduction of dual-targeting CAR-T therapies, such as the one from Pfizer, is noted for significantly extending progression-free survival and overall survival in patients [15] Group 3: Alzheimer's Disease Treatments - The article discusses the launch of the first targeted drug for Alzheimer's disease in China, which aims to modify the disease's progression rather than just alleviate symptoms [25] - It highlights the significance of drugs like donanemab, which is the first to receive breakthrough therapy designation for Alzheimer's treatment, emphasizing its unique mechanism of action [28]